Study to Assess the Safety and Effectiveness of NMRA-335140-501

Major Depressive Disorder Clinical Trial

Official title:

Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Depressive Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06029439
• Other study ID #: NMRA-335140-501
• Secondary ID: KOASTAL-LT
• Status: Recruiting
• Phase: Phase 3
• Start date: November 10, 2023
• Est. completion date: September 2026

Study information

• Verified date: June 2024
• Source: Neumora Therapeutics, Inc.
• Contact: Study Contact
• Email: explore[@]koastalstudy.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), who provide informed consent, and who have no evidence of safety concerns that would preclude treatment with NMRA-335140 may be enrolled into this extension study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 650
• Est. completion date: September 2026
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Key Inclusion Criteria:

Rollover participants are eligible for the study if the following inclusion criteria are met:

• Completed a previous NMRA-335140 Phase 3 MDD study (NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303) according to the completion definition in the parent study protocol.

• Signed an informed consent form (ICF) for this study.

• Willing to comply with the contraception requirements described in the inclusion criteria of the parent study protocol.

• Willing to comply with the concomitant medication/therapy restrictions described in the exclusion criteria of the parent study protocol.

Key Exclusion Criteria:

Rollover participants are excluded from the study if any of the following exclusion criteria are met:

• Diagnosed with another Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) disorder that would have been exclusionary in the parent study (eg, personality disorder, bipolar 1 or 2, schizophrenia, any other psychotic disorder, or moderate or severe substance or alcohol use disorder [excluding nicotine]).

• Considered to be at significant risk of suicide in the judgment of the Investigator. This includes participants who are actively suicidal (eg, any suicide attempts during the parent study) or are at serious suicidal risk as indicated by any current suicidal intent, including a plan, as assessed by the C-SSRS ("Since Last Visit" version, score of "YES" on suicidal ideation Item 4 or 5) and/or based on clinical evaluation by the Investigator; or are homicidal, in the opinion of the Investigator.

• Non-adherent with study medication (took =70% of study drug over any 2-week visit interval) or procedures during the parent study.

• Experienced treatment emergent adverse events (TEAEs) considered related to the study medication from the parent study and judged by the Investigator to be clinically significant to render the participant ineligible for enrollment.

• Have an abnormality on ocular examination that would prohibit continued study participation as determined by the Investigator.

• Use of disallowed concomitant medication or therapy that would have been exclusionary in the parent study, may compromise the safety of the participant, and/or confound the interpretation of protocol assessments.

• Considered by the Investigator to be inappropriate for any other reason.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• NMRA-335140
Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.

Locations

Country	Name	City	State
United States	Neumora Investigator Site	Allentown	Pennsylvania
United States	Neumora Investigator Site	Austin	Texas
United States	Neumora Investigator site	Austin	Texas
United States	Neumora Investigator Site	Bellevue	Washington
United States	Neumora Investigator site	Bellflower	California
United States	Neumora Investigator Site	Berlin	New Jersey
United States	Neumora Investigator Site	Boston	Massachusetts
United States	Neumora Investigator Site	Brooklyn	New York
United States	Neumora Investigator Site	Cedarhurst	New York
United States	Neumora Investigator Site	Chicago	Illinois
United States	Neumora Investigator Site	Colorado Springs	Colorado
United States	Neumora Investigator Site	Dayton	Ohio
United States	Neumora Investigator Site	Decatur	Georgia
United States	Neumora Investigator Site	Everett	Washington
United States	Neumora Investigator Site	Flowood	Mississippi
United States	Neumora Investigator Site	Gainesville	Florida
United States	Neumora Investigator Site	Garden Grove	California
United States	Neumora Investigator Site	Glendale	California
United States	Neumora Investigator site	Huntsville	Alabama
United States	Neumora Investigator Site	Jacksonville	Florida
United States	Neumora Investigator Site	Lafayette	California
United States	Neumora Investigator Site	Las Vegas	Nevada
United States	Neumora Investigator Site	Lauderhill	Florida
United States	Neumora Investigator Site	Lauderhill	Florida
United States	Neumora Investigator site	Little Rock	Arkansas
United States	Neumora Investigator Site	Long Beach	California
United States	Neumora Investigator Site	Los Angeles	California
United States	Neumora Investigator Site	Maitland	Florida
United States	Neumora Investigator Site	Marietta	Georgia
United States	Neumora Investigator Site	Media	Pennsylvania
United States	Neumora Investigator Site	Memphis	Tennessee
United States	Neumora Investigator site	Methuen	Massachusetts
United States	Neumora Investigator site	Miami	Florida
United States	Neumora Investigator site	Miami Lakes	Florida
United States	Neumora Investigator Site	Miami Lakes	Florida
United States	Neumora Investigator Site	New York	New York
United States	Neumora Investigator Site	New York	New York
United States	Neumora Investigator Site	Oceanside	California
United States	Neumora Investigator Site	Orange	California
United States	Neumora Investigator Site	Orlando	Florida
United States	Neumora Investigator Site	Phoenix	Arizona
United States	Neumora Investigator site	Princeton	New Jersey
United States	Neumora Investigator Site	Riverside	California
United States	Neumora Investigator Site	Rogers	Arkansas
United States	Neumora Investigator Site	Saint Charles	Missouri
United States	Neumora Investigator Site	San Jose	California
United States	Neumora Investigator Site	Savannah	Georgia
United States	Neumora Investigator site	Springfield	Massachusetts
United States	Neumora Investigator Site	Tampa	Florida
United States	Neumora Investigator Site	Temecula	California
United States	Neumora Investigator Site	Toms River	New Jersey
United States	Neumora Investigator site	Towson	Maryland
United States	Neumora Investigator Site	Warrenville	Illinois
United States	Neumora Investigator Site	Watertown	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Neumora Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability assessments based on Treatment Emergent Adverse Events (TEAEs) and validated clinical scales	An AE is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE). Clinically significant abnormalities in Clinical Laboratory Evaluations, ECGs, Vital Signs, Physical and Ophthalmological examinations, Corneal Specular Microscopy, Columbia Suicide Severity Rating Scale (C-SSRS), and Sexual Functioning Questionnaire-14 (CSFQ-14) will be reported as TEAEs.	Up to 54 Weeks
Secondary	Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score over time.	Change from baseline in MADRS total score over time will be reported. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.	Baseline and up to Week 54
Secondary	Change from Baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) total score over time	The SHAPS is a 14-item participant-reported instrument which measures anhedonia. It has been shown to be valid and reliable in normal and clinical samples, with adequate construct validity, satisfactory test-retest reliability, and high internal consistency. The scale will be completed by the participant and reviewed by site personnel qualified to oversee completeness. Each of the 14 items has a set of 4 responses, 2 of which endorse agreement (Definitely Agree, Agree) and 2 of which endorse disagreement (Disagree, Strongly Disagree). A total score can be derived by summing the responses; items answered with strongly agree are coded as 1 while a strongly disagree response will be coded as 4. Therefore, scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.	Baseline and up to Week 54
Secondary	Change from Baseline in the Patient Health Questionnaire-9 (PHQ-9) total score over time.	Change from baseline in PHQ-9 total score over time will be reported. The 9-item PHQ-9 scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) diagnostic criteria for recurrent or single episode major depressive disorder (MDD) criteria and used both as a screening tool and a measure of response to treatment for depression. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms.	Baseline and up to Week 54
Secondary	Change from Baseline in PHQ-9 Anhedonia Item #1 over time.	The PHQ-9 is a participant-rated assessment scale for the evaluation of depression symptoms over the past 2 weeks. The PHQ-9 is a reliable and valid measure of depression and depression severity. The questionnaire consists of 9 items and each item is scored from 0 to 3. Participants will be asked how often they have been bothered by symptoms over the past 2 weeks (Not at all [0], Several days [1], More than half the time [2], or Nearly every day [3]). Higher scores indicate higher levels of depression.	Baseline and up to Week 54
Secondary	Change from Baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score over time.	The HAM-A is a clinician-rated instrument administered to assess severity of anxiety, its improvement during the course of treatment, and the timing of such improvement. This instrument will be completed by qualified and trained Investigator site raters based on a semi-structured interview for his/her assessment of the participant. The scale consists of 14 items. Each item is rated on a scale of 0 (feeling not present) to 4 (very severe prevalence of the feeling). The HAM-A total score is the sum of the 14 items and the score ranges from 0 to 56.	Baseline and up to Week 54
Secondary	Change from Baseline in the Clinical Global Impression Scale of Severity (CGI-S)	Change from baseline in the CGI-S total score over time will be reported. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. The CGI-S permits a global evaluation of the participant's condition at a given time.	Baseline and up to Week 54
Secondary	Clinical Global Impression Scale of Improvement (CGI-I) score at each timepoint	The CGI-I scale is a clinician-rated instrument that measures the improvement of the participant's symptoms of depression. It is a 7-point scale where a score of 1 indicates that the participant is "very much improved," a score of 4 indicates that the participant has experienced "no change," and a score of 7 indicates that the participant is "very much worse."	Baseline and up to Week 54
Secondary	Percentage of participants whose MADRS total score decreased by greater than or equal to 50% from Baseline.		Up to Week 54
Secondary	Percentage of participants whose MADRS total score decreased to 10 or less.		Up to Week 54
Secondary	Change from baseline in the Sheehan Disability Scale (SDS) over time.	The SDS is a participant-rated instrument which was developed to assess functional impairment in 3 related domains of work/school, social, and family life. It is a brief self rated tool where the participant rates the 3 items on an anchored 10 point visual analog scale. Following the participant's self assessment, the rater should review the Work/School and Days Lost items to confirm appropriateness of the selected rating by evaluating the impact of MDD symptoms across those sectors. The SDS may be administered via telephone assessment; however, the participant must be provided with a portable document format (PDF) copy of the assessment for reference of the visual analog scale when selecting their ratings.	Baseline and up to Week 54